Skip to content

A phase 2, multicenter, randomized, double blind, active controlled, parallel group study assessing the analgesic effect and safety of two doses of DFL24412 in patients with chronic low back pain compared to Ketoprofen Lysine Salt (KLS)

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-513940-27-00
Enrollment
150
Registered
2024-09-13
Start date
2021-11-19
Completion date
2024-12-30
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic low back pain

Brief summary

• Change From Baseline in Average Daily Low Back Pain (LBP) Intensity as Measured by an 11-point Numeric Rating Scale (NRS) at Week 1

Detailed description

Change From Baseline in Average Daily Low Back Pain (LBP) Intensity as Measured by an 11-point Numeric Rating Scale (NRS) at the follow-up visit [Time Frame:, Day 21], Change from baseline in Neuropathic Pain Symptom Inventory (NPSI) score at week 1, Change from baseline in Douleur Neuropathique en 4 Questions (DN4) score at week 1, Change from baseline in Douleur Neuropathique en 4 Questions (DN4) score at the follow-up visit [ Time Frame: Day 21], Number of Participants Withdrawn Due to Lack of Efficacy Week 1, Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score at Week 1, Change from Baseline in Hospital Anxiety and Depression Scale (HADS) total score at Week 1, Patient Global Impression of Change (PGI-C) Score Week 1, Change From Baseline in European Quality of Life Questionnaire-5 Dimension-5 Level (EQ-5D-5L) to Week 1, Change From Baseline in Work Productivity and Activity Impairment (WPAI) Instrument at Week 1, Number of rescue interventions up to Week 1, Physical examination (see 7.1.2) [time frame: end of treatment visit (Week 1) or withdrawal]., Vital signs: blood pressure, heart rate and Body Temperature and ECG [time frame: end of treatment visit (Week 1) or early withdrawal]., Safety Laboratory Tests: hematocrit, hemoglobin, red blood cells, platelets, white blood cells, differential white blood cells count, sodium, potassium, calcium, serum creatinine, urea, serum albumin, total bilirubin, fractionated bilirubin, ALT, AST, ALP, lypases and amylases [time frame: end of treatment visit (Week 1) or early withdrawal]., Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) [time frame: throughout the study].

Interventions

DRUGOKi 80 mg granulato per soluzione orale
DRUGKLS-GABA 40mg-17mg
DRUGKLS-GABA 80mg-34mg

Sponsors

Dompe' Farmaceutici S.p.A.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
• Change From Baseline in Average Daily Low Back Pain (LBP) Intensity as Measured by an 11-point Numeric Rating Scale (NRS) at Week 1

Secondary

MeasureTime frame
Change From Baseline in Average Daily Low Back Pain (LBP) Intensity as Measured by an 11-point Numeric Rating Scale (NRS) at the follow-up visit [Time Frame:, Day 21], Change from baseline in Neuropathic Pain Symptom Inventory (NPSI) score at week 1, Change from baseline in Douleur Neuropathique en 4 Questions (DN4) score at week 1, Change from baseline in Douleur Neuropathique en 4 Questions (DN4) score at the follow-up visit [ Time Frame: Day 21], Number of Participants Withdrawn Due to Lack of Efficacy Week 1, Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score at Week 1, Change from Baseline in Hospital Anxiety and Depression Scale (HADS) total score at Week 1, Patient Global Impression of Change (PGI-C) Score Week 1, Change From Baseline in European Quality of Life Questionnaire-5 Dimension-5 Level (EQ-5D-5L) to Week 1, Change From Baseline in Work Productivity and Activity Impairment (WPAI) Instrument at Week 1, Number of rescue interventions up to

Countries

Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026